Table 2 Identified utility studies by line of treatment
Author, year, country | Line of treatment | Health state | Instrument | Treatment |
|---|---|---|---|---|
First linea | ||||
Handorf 2012 USA [70] | 1 L | Stage IV adenocarcinoma SDis, PD, SDis+AEs (neutropenia, pneumothorax, haemorrhage, thrombocytopenia, thrombosis) | Expert opinion estimates,b published sources | NTS |
Nafees 2016 Multinational and UK [68] | 1 L | Metastatic NSCLC common grade III/IV toxicities (neutropenia, febrile neutropenia, fatigue, nausea and vomiting, diarrhea, hair loss, rash), bleeding, hypertension | TTO (general public) | NTS |
≥ First linec | ||||
Chevalier 2013 France and nine other countries [38] | 1 L, 2 L, 3/4 L and BSC | Advanced/metastatic NSCLC 1 L, 2 L, 3/4 L PF and PD | EQ-5D | NTS |
Chouaid 2013 Multinational [39] | 1 L 55.1% 2 L 24.7% 3/4 L 17.9% BSC 2.3% | Advanced/metastatic NSCLC 1 L, 2 L, 3/4 L, BSC and mixed line PF and PD | EQ-5D, EQ-VAS | NTS |
Iyer 2013 France, Germany [46] | 1 L 52% 2 LL 48% | Advanced/metastatic NSCLC | EQ-5D | NTS |
Second line | ||||
Blackhall 2014 Multinational [41] | 2 L after progression on platinum-based 1 L therapy | Locally advanced/metastatic ALK+ NSCLC BL and treatment-specific utilities (not PSS) | EQ-5D EQ-VAS | CRZ PEM DOC |
Huang 2016 Worldwide [45] | 2 L after platinum-based therapy | Advanced PD-L1+ NSCLC NTS PF, PD NTS time to death | EQ-5D | PEMB DOC |
Langley 2013 UK, Australia [48] | 2 Ld | Treatment-specific stage IV NSCLC with BM at BL and after certain time points on treatment | EQ-5D | OSC WBRT + OSC |
Nafees 2008 UK [69] | 2 L | Metastatic NSCLC PD, RES, SDis, common grade III/IV toxicities (neutropenia, febrile neutropenia, fatigue, nausea and vomiting, diarrhea, hair loss, rash) | SG (general public) | NTS |
Novello 2015 Multinational [49] | 2 L | Stage III/IV recurrent NSCLC (SQ and NSQ) treatment-specific at BL and certain time points on treatment (≤ 30 weeks) | EQ-5D, EQ-VAS | NIN + DOC PLA + DOC |
Reck 2015 Multinational [50] | 2 L | Advanced SQ NSCLC treatment-specific at BL reported. Collected also for up to 1 year but values NR in abstract | EQ-5D, EQ-VAS | NIVO DOC |
Rudell 2016 USA, Canada, Hong Kong, Italy, Japan, Republic of Korea, Spain, Taiwan [57] | 2 L | Advanced EGFR+ NSCLC, treatment-specific at BL and 36 weeks on OSI | EQ-VAS | OSI |
Schuette 2012 Germany, Austria [51] | 2 L | Stage III/IV NSCLC treatment-specific at BL, 6 weeks (second cycle) and sixth cycle | EQ-5D EQ-VAS | PEM |
Vargas 2009 Mexico [72] | 2 L after previous CHEMO | NSCLC, stage NR (assumed advanced), treatment-specific not PSS | Global QoL index | ERL Taxanes |
≥ Second line | ||||
Chen 2010 UK/multinational [64] | 2 L, 3 L and BSC | Stage IIIb/IV EGFR+ NSCLC treatment-specific (not PSS) On/after DOC 2 L On/after PEM 2 L On ERL 3 L BSC | SG (general public) | DOC PEM ERL BSC |
Griebsch 2014 Multinational [37] | 2LLe and treatment-naïve | Stage IIIb with pleural effusion or stage IV NSCLC adenocarcinoma treatment-specific and NTS effect of progression | EQ-5D, EQ-VAS | AFA BSC CIS/PEM |
Hirsh 2013 Multinational [40] | 2LLf | Stage IIIb/IV NSCLC BL and treatment-specific on oral AFA 50 mg q.d. + BSC or PLA + BSC | EQ-5D | AFA + BSC PLA + BSC |
Stewart 2015 Canada [56] | Targeted therapy 84% 3LL 25% RCT 22% | Metastatic EGFR+ NSCLC, all patients not PSS PR/SDis EGFR TKI RES CHEMO RES GEF RES ERL RES OSI PD EGFR TKI | EQ-5D-3 L | GEF ERL OSI |
Schwartzberg 2015 USA, Canada [60] | 2 LL | Squamous and non-squamous stage IIIb/IV NSCLC treatment-specific weeks 6–30 Treatment-specific PR, SDis and PD weeks 6–30 | EQ-VAS | NIVO |
Treatment line not specified | ||||
Bradbury 2008 Canada [42] | Unclear | Advanced NSCLC Treatment-specific (not PSS) | EQ-5D | ERL BSC |
Chang 2016 South Korea [63] | NR | Advanced NSCLC from > 360 days before death to < 30 days before death (not PSS) | TTO (general public) | NTS |
Dansk 2016 UK [43] | NR | Synthesized advanced NSCLC PF, PD used in NICE HTAs Trial-based PF, PD Non-trial based PF, PD | EQ-5D | NTS |
Doyle 2008 UK [65] | NR | Metastatic NSCLC SDis, RES, severe symptoms (cough, dyspnoea, pain) | SG (general public) | NTS |
Grunberg 2009 USA [58] | NR | Mixed cancer population chemotherapy-related nausea, vomiting, and nausea and vomiting, of different severities | SG (patient) | CHEMO |
Grutters 2010 Netherlands [44] | NR | NSCLC with grade 3+ dyspnoea | EQ-5D | NTS |
Jang 2010 Canada [47] | NR | Stage IV NSCLC and locally advanced NSCLC | EQ-5D | NTS |
Linnet 2015 Denmark [62] | Unclear | Metastatic NSCLC second and third CHEMO cycles on oral VINO Patient and caregiver utilities reported | SF-12 | VINO |
Lloyd 2005 UK [66] | NR | Stage IV NSCLC RES, SDis i.v. treatment, SDis oral treatment, PD, end of life | SG (general public) | NTS |
Lloyd 2008 [59] | Previous CHEMO | Anaemia by haemoglobin level | General public SG, patient TTO | NTS |
Manser 2006 Australia [61] | NR | Stage IV NSCLC | AQoL | NTS |
Matza 2014 UK and Canada [67] | NR | Stage IV cancer with BMs and different types of SRE (spinal cord compression with/without paralysis, fracture of leg, fracture of rib, fracture of arm), radiation treatment (2 weeks, 5 appointments/week), radiation treatment (2 appointments), surgery to stabilize bone | TTO (general public) | NTS |
Tabberer 2006 UK [52] | NR | Advanced NSCLC RES, SDis, SDis oral treatment, SDis i.v. treatment, PD, near death, AEs (neutropenia, febrile neutropenia, nausea, diarrhoea, rash, stomatitis, neuropathy) | EQ-5D (general public) | NTS |
Trippoli 2001 Italy [53] | NR | Metastatic NSCLC | EQ-5D, EQ-VAS | NTS |
Westwood 2014 [71] | NR for other disutilities | Advanced NSCLC Disutility for anaemia and for i.v./oral treatment mode | SG NR for other disutilities | NTS ERL i.v. tx |
Yang 2014 Taiwan [54] | NR | NSCLC operable (I–IIIA) and NSCLC inoperable (IIIB/IV) | EQ-5D | NTS |
Yokoyama 2013 Japan [55] | NR | Stage IIIB/IV mixed NSCLC/SCLC with bone metastasis and SRE (pathologic fracture, radiation or surgery to bone lesion, spinal cord compression or hypercalcaemia) | EQ-5D | NTS |